A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients

NCT00518622 Phase 1 COMPLETED Results posted

The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	40
Start date	2007-07
Completion	2008-09

Conditions

• Hepatitis C

Interventions

• Comparator: MK7009
• Comparator: Placebo

Primary outcomes

• Safety and Tolerability of MK7009 — 14 days after completion of study therapy
  Number of participants who reported adverse experiences while on study medication as well as for 14 days after completion of study medication
• Antiviral Activity of MK7009 — Baseline and Day 8
  Change from Baseline in Log10 IU/mL hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 8